Claims
- 1. An adjuvant comprising at least one Epstein-Barr virus (EBV) Gp350/220 sequence that binds to CR2.
- 2. The adjuvant of claim 1 comprising at least two Epstein-Barr virus (EBV) Gp350/220 sequences.
- 3. The adjuvant of claim 1 wherein the sequence is a recombinant fusion protein.
- 4. The adjuvant of claim 3 wherein the fusion protein contains multiple copies of Gp350/220 sequence.
- 5. A vaccine comprising:
1) the adjuvant of claim 1; and 2) and at least one moiety,
wherein at least one moiety contains at least one antigenic epitope other than an epitope of EBV Gp350/220, dissolved or suspended in a pharmaceutically acceptable carrier.
- 6. A method of treating a patient comprising administering the vaccine of claim 5.
- 7. The method of claim 6 wherein the vaccine elicits antibodies against EBV Gp350/220 and against at least one antigenic epitope of the moiety other than an epitope of EBV Gp350/220.
- 8. An immunogenic composition comprising:
1) at least one moiety,
wherein at least one moiety contains at least one antigenic epitope other than an epitope of EBV Gp350/220; and 2) at least one EBV Gp350/220 sequence that binds to CR2, directly or indirectly conjugated to the at least one moiety.
- 9. The composition of claim 8 comprising at least two Epstein-Barr virus (EBV) Gp350/220 sequences.
- 10. The composition of claim 8 comprising multiple copies of at least one antigenic epitope other than an epitope of EBV Gp350/220.
- 11. The composition of claim 9 comprising multiple copies of at least one antigenic epitope other than an epitope of EBV Gp350/220.
- 12. The composition of claim 8 wherein at least one moiety and at least one EBV Gp350/220 sequence comprise a recombinant fusion protein.
- 13. The composition of claim 9 wherein at least one moiety and at least two EBV Gp350/220 sequences comprise a recombinant fusion protein.
- 14. A vaccine comprising the composition of claim 8 dissolved or suspended in a pharmaceutically acceptable carrier.
- 15. A method of treating a patient comprising administering the vaccine of claim 14 to a patient.
- 16. The method of claim 15 wherein the vaccine elicits antibodies against EBV Gp350/220 and against at least one antigenic epitope of the moiety other than an epitope of EBV Gp350/220.
- 17. A method of stimulating an immune response comprising contacting B cells with the immunogenic composition of claim 8.
- 18. A nucleic acid vector which directs the expression of Gp350/220 sequences alone, or as a recombinant fusion protein.
- 19. The nucleic acid vector of claim 18 wherein the nucleic acid is contained within a biological vector capable of expressing the Gp350/220 or Gp350/220 fusion protein.
- 20. A method of treating a patient comprising administering the nucleic acid vector of claim 18.
- 21. A method of treating a patient comprising administering the biological vector of claim 19.
- 22. The adjuvant of claim 1 wherein the Gp350/220 sequence is a Gp350/220 analog.
- 23. The vaccine of claim 5 wherein the Gp350/220 sequence is a Gp350/220 analog.
- 24. The immunogenic composition of claim 8 wherein the Gp350/220 sequence is a Gp350/220 analog.
- 25. The nucleic acid vector of claim 18 wherein the Gp350/220 sequence is a Gp350/220 analog.
- 26. The immunogenic composition of claim 8 wherein at least one moiety is conjugated to the at least one EBV Gp350/220 sequence using CDAP (1-cyano-4-“dimethylamino”-pyridinium tetrafluoroborate) chemistry.
GOVERNMENT INTEREST
[0001] The invention described herein may be manufactured, licensed and used for governmental purposes without the payment of any royalties to us thereon.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60089158 |
Jun 1998 |
US |